Search

Displaying results 2031 - 2040 of 10000 in total
  1. Target

    tRNA-dihydrouridine(20) synthase [NAD(P)+]-like

    go.drugbank.com/bio_entities/BE0020091
    EnzymeHumans

    Specifically modifies U20 in cytoplasmic tRNAs (PubMed:38680565). Activity depends on the presence of guanosine at position 19 in the tRNA substrate (PubMed:38680565). … Catalyzes the NADPH-dependent synthesis of dihydrouridine, a modified base found in the D-loop of most tRNAs (PubMed:15994936, PubMed:26429968, PubMed:30149704, PubMed:34798057, PubMed:38680565).

    Synonyms: Up-regulated in lung cancer protein 8
  2. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. … [L41524] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.

  3. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. … [L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical trials.

    Categories: Drugs Used in Hereditary Angioedema
  4. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. … [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  5. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata. … Deuruxolitinib is a deuterated form of [ruxolitinib] that selectively inhibits Janus kinases (JAK) JAK1 and JAK2.

    Categories: Bile Salt Export Pump Inhibitors
  6. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 … It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.

  7. Indication

    Bone Diseases, Infectious

    go.drugbank.com/conditions/DBCOND0076351
    Drugs: Cephalexin · Tobramycin
    Synonyms: Infection in Bone
  8. Indication

    Diabetes Mellitus

    go.drugbank.com/conditions/DBCOND0027886
    Drugs: Ammonium chloride · Borneol · Insulin aspart · Insulin degludec · Insulin glargine · Insulin glulisine +4 more
    Synonyms: Ketoacidosis in diabetes mellitus
  9. Indication

    Insomnia

    go.drugbank.com/conditions/DBCOND0017531
    Drugs: Amitriptyline · Brotizolam · Butabarbital · Cinolazepam · Clotiazepam · Daridorexant +31 more
    Synonyms: Difficulty in sleep initiation
  10. Drug

    mRNA-1345

    go.drugbank.com/drugs/DB18739
    ApprovedInvestigational

    mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L52380] In June 2025, its US indication was expanded to include patients 18-59 years old at increased risk of disease.